Table 2.
Care continuum outcomes at baseline, follow-up, and change between surveys in HIV-positive people who inject drugs and men who have sex with men in 21 cities in India.
| Baseline (2012/13) | Follow-up (2016/17) | Change between surveys | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Outcome | MSM (%) | PWID (%) | P valuea | MSM (%) | PWID (%) | P valuea | MSM (percentage points) |
PWID (percentage points) |
Difference in changeb
(95% CI) |
| Aware of status | 42.0 | 37.8 | 0.59 | 77.8 | 49.2 | 0.005 | 35.8 | 11.5 | 27.4 (11.6, 43.2) |
| Care in prior 6 months | 32.1 | 19.2 | 0.091 | 63.0 | 26.6 | 0.001 | 30.9 | 7.4 | 32.2 (16.2, 48.2) |
| Use of ART | 30.4 | 16.5 | 0.15 | 63.8 | 25.6 | 0.002 | 33.5 | 9.0 | 33.2 (14.5, 51.8) |
| Viral load suppressed | 35.3 | 23.7 | 0.079 | 56.1 | 32.4 | 0.008 | 20.8 | 8.7 | 15.4 (−0.1, 30.8) |
Percentages are pooled site-level estimates, weighted using respondent-driven sampling-II weights. MSM, men who have sex with men; PWID, people who inject drugs; CI, confidence interval (Heckathorn, 2002).
a
P value testing difference in care continuum indicator between MSM and PWID.
b
Difference in change (MSM minus PWID) was estimated in a model that adjusted for prevalence of the outcome at baseline and for assignment to intervention or control in the cluster-randomized trial.